

OPEN ACCESS

EDITED AND REVIEWED BY Hridayesh Prakash, Amity University, India

*CORRESPONDENCE
Haiyan Wang
Wanghaiyan@qhu.edu.cn

RECEIVED 25 July 2025
ACCEPTED 27 August 2025
PUBLISHED 02 September 2025

CITATION

Wang T, Sun J, Wang L, Lin Y, Wu Z, Jia Q, Zhang S, An J, Ma X, Wu Q, Su Z and Wang H (2025) Correction: Therapeutic potential of isochlorogenic acid A from *Taraxacum officinale* in improving immune response and enhancing the efficacy of PD-1/PD-L1 blockade in triple-negative breast cancer. *Front. Immunol.* 16:1672972. doi: 10.3389/fimmu.2025.1672972

COPYRIGHT

© 2025 Wang, Sun, Wang, Lin, Wu, Jia, Zhang, An, Ma, Wu, Su and Wang. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Correction: Therapeutic potential of isochlorogenic acid A from *Taraxacum officinale* in improving immune response and enhancing the efficacy of PD-1/PD-L1 blockade in triple-negative breast cancer

Tangyi Wang¹, Jingwei Sun², Li Wang¹, Yuxin Lin¹, Zhijing Wu¹, Qiangqiang Jia³, Shoude Zhang³, Juan An^{1,4,5}, Xueman Ma^{1,4,5}, Qiong Wu^{1,4,5}, Zhanhai Su^{1,4,5} and Haiyan Wang^{1,4,5}*

¹Department of Basic Medical Sciences, Qinghai University Medical College, Xining, Qinghai, China, ²Department of Medical Laboratory, Qinghai Provincial People's Hospital, Xining, Qinghai, China, ³State Key Laboratory of Plateau Ecology and Agriculture, Qinghai University, Xining, Qinghai, China, ⁴Research Center for High Altitude Medicine, Qinghai University, Xining, Qinghai, China, ⁵Key Laboratory of the Ministry of High Altitude Medicine, Qinghai University, Xining, Qinghai, China

KEYWORDS

immune checkpoint blockade, *Taraxacum officinale*, PD-1/PD-L1 inhibitor 2, tumor microenvironments, triple-negative breast cancer

A Correction on

Therapeutic potential of isochlorogenic acid A from *Taraxacum* officinale in improving immune response and enhancing the efficacy of PD-1/PD-L1 blockade in triple-negative breast cancer

By Wang T, Sun J, Wang L, Lin Y, Wu Z, Jia Q, Zhang S, An J, Ma X, Wu Q, Su Z and Wang H (2025) Front. Immunol. 16:1529710. doi: 10.3389/fimmu.2025.1529710

There was a mistake in **Figure 7F** as published. The error was caused by the use of placeholder images during the typesetting process to maintain layout consistency; due to oversight, some placeholders were not replaced with the correct images. The corrected **Figure 7F** appears below.

The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Wang et al. 10.3389/fimmu.2025.1672972




FIGURE 7 ICGA-A and CRA inhibited mRNA and protein expression levels of metabolic-associated proteins and pathways. (A) Venn diagram of DEGs in MDA-MB-231 cells treated with ICGA-A and CRA. (B) The top 10 GO terms in the BP, CC, and MF classifications of overlapping genes with MDA-MB-231. The x-axis represents the enriched terms, and the y-axis represents the enrichment score. (C) Top 20 KEGG pathways. KEGG pathways enrichment for the overlapping genes with MDA-MB-231. The x-axis represents the gene ratio (p < 0.05), and the y-axis represents the enriched terms. (D) The ranking of ICGA-A scored by HTS² in a library of over 20,000 compounds. (E) Heatmap of the intersecting genes between RNA-seq and network pharmacology targets. (F) ICGA-A and CRA decreased the phosphorylation levels of FAK, PI3K, AKT, and mTOR. *p < 0.05, **p < 0.01, ***p < 0.001 vs. DMSO.